An In-Depth Exploration In examining recent analyst actions, we gain insights into how financial experts perceive Lam Research. The following summary outlines key analysts, their recent ...

Marseille, France, March 25, 2025 - Vect-Horus, a privately held biotechnology company that designs and develops molecular vectors facilitating the targeted delivery of therapeutic molecules and ...

At the same time, financial pressures facing the university system are prompting institutions to shift funding away from long-term research posts to save money. University clinical research is ...

today provided a clinical programs update and reported financial results for the full year ended December 31, 2024. “We are pleased with the progress made over the past year and in recent weeks ...

Discover Corvus Pharmaceuticals' Q4 2024 earnings insights, highlighting soquelitinib's trial progress, upcoming milestones for 2025, and robust ...

Appointed Josiah Craver as Senior Vice President of Finance and later as Principal Financial ... clinical trials and one-time employee termination benefits primarily offset by lower preclinical ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

Ethical Partners was the seller behind 10 per cent of ACL and just under 15 per cent of NobleOak traded by E&P Financial and Barrenjoey respectively on Thursday.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.